Investment Advisor Sees Greater Operating Leverage in Pharma, Predicts Outperformance Over IT Services
An investment advisor with over a decade of experience in asset allocation, portfolio construction, and quantitative investments believes that the pharmaceutical industry has greater profitability than the IT services industry, which could lead to outperformance in the coming years.
The advisor, who asked to remain anonymous, attributed this to the fact that pharmaceutical companies have higher gross margins and lower operating expenses than IT services companies. This means that for every dollar in revenue that a pharmaceutical company generates, it keeps more of that dollar as profit. IT services companies, on the other hand, have to spend more of their revenue on things like salaries, rent, and marketing.
The advisor also noted that pharmaceutical companies have a longer product lifecycle than IT services companies. This means that once a pharmaceutical company develops a new drug, it can generate revenue from that drug for many years to come. IT services companies, on the other hand, have to constantly develop new products and services in order to keep up with the ever-changing technology landscape.
As a result of these factors, the advisor believes that pharmaceutical companies have a greater ability to generate profits and cash flow than IT services companies. This could lead to outperformance in the coming years, as investors increasingly favor companies with strong profitability and cash flow.
The advisor’s views are in line with those of some other analysts. In a recent report, Morgan Stanley analysts said that they believe the pharmaceutical industry is “one of the most attractive sectors for long-term investors.” The analysts pointed to the industry’s strong growth prospects, as well as its high profitability and cash flow generation.
It is important to note that the pharmaceutical industry is not without its risks. Drug development is a long and expensive process, and there is always the risk that a new drug will fail in clinical trials or be rejected by regulators. However, the advisor believes that the potential rewards of investing in the pharmaceutical industry outweigh the risks.
Overall, the advisor’s views suggest that the pharmaceutical industry could be a good investment for investors who are looking for companies with strong profitability and cash flow generation. The industry is also expected to grow at a healthy pace in the coming years, which could lead to further outperformance.
Related News
- 22 Sep
HDFC Bank stock expected to re-rate in next 12-18 months, says Motilal Oswal’s Nitin Aggarwal
Aggarwal is bullish on HDFC Bank's long-term prospects, but he believes that investors should wait and see how the bank executes in the near term.
- 22 Sep
Sai Silks’ IPO attracts lukewarm response, analysts raise concerns
Sai Silks Kalamandir's IPO received a lukewarm response with a subscription rate of just 0.07 times. Analysts have raised concerns about the company's high debt levels, intense competition in the industry, and the fact that half of the issue size is an OFS. The company also has 30 percent of its promoter holdings pledged. Despite these concerns, the company's management is confident about its growth prospects.
- 22 Sep
PSU bank shares make a comeback on JPMorgan’s index inclusion decision
PSU bank shares made a strong comeback on September 22, after JPMorgan's decision to include Indian government bonds in its emerging-market index boosted investor sentiment. However, analysts are urging caution with regard to the PSU bank space, citing the risks of investing in smaller PSU banks and the potential for divestment in some of the larger banks. Investors should carefully consider the risks and rewards before investing in PSU bank shares.
- 22 Sep
SEBI penalizes 11 entities for non-genuine trades in illiquid stock options segment
The Securities and Exchange Board of India (SEBI) has penalized 11 entities for non-genuine trades, fined 2 entities for flouting disclosure rules, and suspended the registration of 1 research firm for violating regulatory norms. SEBI's actions are a reminder to market participants that they must comply with all regulatory requirements. Investors should be aware of these risks and take necessary precautions to protect themselves.
- 22 Sep
Zaggle Prepaid Ocean Services Stock Makes Weak Debut, Analysts Recommend Selling
Zaggle Prepaid Ocean Services stock made a muted debut on bourses on September 22, listing at a premium of just 0.6% over the IPO price. Analysts have recommended selling the stock on the opening day, citing its high P/E valuation, debt-to-equity ratio, and negative cash flow.
Leave a Reply